Artivion (NYSE:AORT) CAO Amy Horton Sells 641 Shares of Stock

Artivion, Inc. (NYSE:AORT) CAO Amy Horton sold 641 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $38.02, for a total transaction of $24,370.82. Following the completion of the sale, the chief accounting officer owned 132,514 shares of the company’s stock, valued at $5,038,182.28. This trade represents a 0.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Amy Horton also recently made the following trade(s):

• On Tuesday, February 24th, Amy Horton sold 830 shares of Artivion stock. The stock was sold at an average price of $35.69, for a total transaction of $29,622.70.
• On Monday, February 23rd, Amy Horton sold 1,731 shares of Artivion stock. The shares were sold at an average price of $37.59, for a total transaction of $65,068.29.
• On Monday, December 8th, Amy Horton sold 4,572 shares of Artivion stock. The stock was sold at an average price of $44.42, for a total value of $203,088.24.

Artivion Stock Performance

NYSE AORT opened at $38.56 on Wednesday. The business has a 50 day moving average price of $41.59 and a 200 day moving average price of $42.95. The company has a market capitalization of $1.85 billion, a P/E ratio of 192.81 and a beta of 1.60. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $48.25. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The business had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. The business’s revenue for the quarter was up 19.2% compared to the same quarter last year. Sell-side analysts expect that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on AORT shares. Needham & Company LLC reaffirmed a “buy” rating and set a $58.00 price target on shares of Artivion in a research note on Monday, February 2nd. Wall Street Zen cut shares of Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Canaccord Genuity Group reduced their price target on Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research note on Friday, February 13th. Oppenheimer reaffirmed an “outperform” rating and issued a $50.00 price objective on shares of Artivion in a research report on Friday, November 7th. Finally, Citizens Jmp increased their target price on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $48.97.

Hedge Funds Weigh In On Artivion

Hedge funds and other institutional investors have recently modified their holdings of the company. Aster Capital Management DIFC Ltd lifted its position in Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after buying an additional 519 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Artivion during the third quarter worth about $27,000. Larson Financial Group LLC grew its stake in shares of Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after buying an additional 563 shares in the last quarter. USA Financial Formulas lifted its position in Artivion by 163.5% during the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after acquiring an additional 703 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its position in Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after acquiring an additional 538 shares in the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Analysts maintain a constructive view — the consensus rating reported is “Moderate Buy,” and several firms have reiterated buy/outperform ratings and mid‑to‑high price targets, which can support demand for AORT shares. Artivion Receives Consensus Rating
• Positive Sentiment: Management will present virtually at the Oppenheimer Healthcare MedTech & Services Conference (fireside chat), giving the company a chance to update guidance, product progress or commercialization milestones — an event that often attracts buy‑side attention. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Institutional investors have been adding to positions (Invesco, Summit Partners, Goldman Sachs, Two Sigma among those increasing exposure), which can provide steady bid support and signal confidence from larger, professional investors. MarketBeat – Artivion Institutional Activity
• Neutral Sentiment: Recent quarterly results beat revenue and EPS estimates (Feb. 12), showing top‑line growth; this underpins the bull case but may already be priced in given prior analyst upgrades. MarketBeat – Artivion Earnings Summary
• Negative Sentiment: Multiple senior insiders sold shares on March 2 (CEO James Mackin sold ~14.9k shares; EVP Lance Berry and several SVPs also sold), a cluster of sales that markets often interpret as a negative signal even though insiders retain large holdings. See the SEC Form 4 for details. SEC Form 4 – Mackin

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.